MétaCan
Menu
Back to cohort
Record W4405374998 · doi:10.1016/j.iotech.2024.100749

120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial

2024· article· en· W4405374998 on OpenAlexaff
Kristof Cuppens, G. Lo Russo, Óscar Juan, E. Felip, Ma Carmen Areses Manrique, Alberto Chiappori, E. Govaerts, P.K. Cheema, L. Greillier, L. Toschi, Eric Schaefer, M. Clouseau, C. Martinoli, Hussein Shehade, Natalie Byrne, M. Fox, M. Rossetti, Olivier De Henau, S. Ross, S. Peters

Bibliographic record

VenueImmuno-Oncology Technology · 2024
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsWilliam Osler Health SystemBrampton Civic Hospital
Fundersnot available
KeywordsMedicineOncologyChemotherapyInternal medicineImmune checkpointImmune systemImmunotherapyImmunologyCancer

Abstract

fetched live from OpenAlex

Immunosuppressive adenosine accumulates at high levels in advanced non-small cell lung cancer (NSCLC), where treatment options remain limited following immune checkpoint inhibitor (ICI) therapy. Inupadenant, a selective adenosine-2A receptor (A2AR) inhibitor, counteracts the adenosine immunosuppressive effects. Combining inupadenant with standard chemotherapy may enhance anti-tumor immunity leading to more durable clinical outcomes in advanced NSCLC.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.276
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueImmuno-Oncology TechnologySame topicCancer Immunotherapy and BiomarkersFrench-language works237,207